Previous 10 | Next 10 |
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021....
A, ACC, ADC, AGR, APEN, API, APLE, AROC, AWR, AXGN, BCC, BLKB, BNL, BRFS, BRY, BTG, BWXT, BXC, CDNS, CERS, CGBD, CSGP, CUTR, CWH, CZR, EPR, EXAS, FANG, FPI, GKOS, GMBL, GTE, HALO, HCC, HIMS, HTGC, INDI, KTOS, LAND, LILA, LPI, MAXR, MELI, MOS, MTDR, NDSN, NHI, NU, O, OMAB, PANW, PEB, PEN, OTCP...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several executive leadership changes to support the company’s future gro...
Conference Call and Webcast Scheduled for 1:30 p.m. PST Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth qua...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-301...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-302...
Approximately 70% of Subjects were Well-Controlled on iDose TR with the Same or Fewer Topical IOP-Lowering Medications at 36 Months vs. Screening Favorable Safety Profile Through 36 Months Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmac...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administratio...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 40 th Annu...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effecti...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...